Key Capital Corporation (KCPC)
| Market Cap | 4.60K +2,401.1% |
| Revenue (ttm) | 500.00K |
| Net Income | -401.49K |
| EPS | -0.02 |
| Shares Out | 46.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Open | 0.0001 |
| Previous Close | 0.000001 |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | 0.000001 - 0.0001 |
| Beta | 76.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Key Capital
Key Capital Corporation, a development stage company, engages in the mining and mining industry financing business worldwide. The company operates as a streaming, structured finance, and equity funder of mining projects through funding agreements for an interest in the production of mines containing gold, silver, base metals, or energy products. It is also involved in funding resource and energy projects through its online lending platform. In addition, the company, through its subsidiary, GeoGlobal Resources, Inc., engages in the exploration a... [Read more]
News
Key Capital Offers to Help India COVID Crisis with Major Aid Potential via its 24/7 Immune Supplement
MaxCellLife 24/7 Immune Supplement has been Reported Effective for COVID-19, Colds and Flu, with 90% Reduction in COVID-19 Virus Infectivity Additionally Reported Through Independent University Resear...
Key Capital HAP-V+ Immune Supplement Reported Effective Against COVID-19, and Colds and Flu
90% Reduction in COVID-19 Virus Infectivity Reported Through Independent University Research Study NEW YORK, NY / ACCESSWIRE / April 26, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that Imm...
Key Capital Launches Unique Natural Mental Health Supplement - MaxCellLife MIND
MaxCellLife MIND, a Proprietary M.Vaccae and Magnesium Compound, targets the Multi-Billion Anxiety, Stress and Depression Market NEW YORK, NY / ACCESSWIRE / April 8, 2021 / KEY CAPITAL CORPORATION (OT...
Key Capital Launches MaxCellLife.com to Market Unique Supplement and Skincare Products
Jennifer Reilly appointed Marketing Director to Lead MaxCellLife.com Launch NEW YORK, NY / ACCESSWIRE / April 7, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises the Company is launching https:/...
Key Capital to Focus on Oral Pill Cancer Treatment Success
Therapeutic Cancer Vaccines - Key Capital Reports Progress and Development Priority NEW YORK, NY / ACCESSWIRE / March 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises the following to clarif...
Key Capital Leads Oral Pill Vaccines Race with Immunitor Partnering and Strong Patenting
Multiple Human Clinical Trials Have Demonstrated Unprecedented Success in Cancers, Including HCC Liver Cancer, Vascular and Other Diseases, and Viruses NEW YORK, NY / ACCESSWIRE / March 3, 2021 / KEY ...
Key Capital COVID-19 Oral Pill Vaccine Records 90% Reduction in Virus Infectivity in Early Study
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine NEW YORK, NY / ACCESSWIRE / January 18, 2021 / KEY CAPITAL CORPORATION (...
Key Capital Advises Urgent Global Need For COVID-19 Oral Pill Therapeutic Vaccine
NEW YORK, NY / ACCESSWIRE / January 6, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it is fast becoming clear that the approach to global COVID-19 vaccination is in crisis. While WHO ad...
Key Capital COVID-19 Oral Pill Vaccine Update
Key Capital Invites Partnering Inquiries for COVID-19 Therapeutic Vaccine NEW YORK, NY / ACCESSWIRE / December 28, 2020 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that the Company, through Key ...